Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 440Rectal Neoplasms 209Colonic Neoplasms 201Pancreatic Neoplasms 131Stomach Neoplasms 116Neoplasm Metastasis 97Neoplasms 63Esophageal Neoplasms 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Lymphoma 49Leukemia 41Carcinoma, Hepatocellular 40Adenocarcinoma Of Esophagus 37Burkitt Lymphoma 33Adenocarcinoma 29Cholangiocarcinoma 26Biliary Tract Neoplasms 22Carcinoma, Non-Small-Cell Lung 21Gastrointestinal Neoplasms 20Lymphoma, Non-Hodgkin 19Gallbladder Neoplasms 19Esophageal Squamous Cell Carcinoma 15Osteosarcoma 14Bile Duct Neoplasms 14Unspecified Adult Solid Tumor, Protocol Specific 13Lymphoma, Large B-Cell, Diffuse 13Liver Neoplasms 13Leukemia, Biphenotypic, Acute 13Ovarian Neoplasms 12Leukemia, Myeloid, Acute 12

Interventions

Bevacizumab 5pembrolizumab 4Gemcitabine 4Cisplatin 4napabucasin 3Paclitaxel 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2anlotinib 2Taxes 2Sunitinib 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Leucovorin 2Immunotherapy 2Fluorouracil 2Carboplatin 2sipuleucel-T 1pralsetinib 1palbociclib 1olaparib 1niraparib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1ixabepilone 1interferon gamma-1b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Glandular and Epithelial × Leucovorin × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡